Related references
Note: Only part of the references are listed.Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer
Adriaan Vanderstichele et al.
GYNECOLOGIC ONCOLOGY (2022)
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study
Elizabeth M. Swisher et al.
GYNECOLOGIC ONCOLOGY (2022)
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer
Nicoletta Colombo et al.
GYNECOLOGIC ONCOLOGY (2022)
European cancer mortality predictions for the year 2022 with focus on ovarian cancer
M. Dalmartello et al.
ANNALS OF ONCOLOGY (2022)
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Rebecca Kristeleit et al.
LANCET ONCOLOGY (2022)
Lymphadenectomy in ovarian cancers: a meta-analysis of hazard ratios from randomized clinical trials
Roli Purwar et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2022)
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
Deborah K. Armstrong et al.
Journal of the National Comprehensive Cancer Network (2022)
Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial
X. H. Wu et al.
ANNALS OF ONCOLOGY (2021)
Homologous recombination proficiency in ovarian and breast cancer patients
Justin Fortune Creeden et al.
BMC CANCER (2021)
Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance
Dae-Seok Kim et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2021)
Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort
Lingying Wu et al.
GYNECOLOGIC ONCOLOGY (2021)
PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival
Fengping Shao et al.
Aging-US (2021)
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
Susana Banerjee et al.
LANCET ONCOLOGY (2021)
Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers
Dawn C. Janysek et al.
TRANSLATIONAL ONCOLOGY (2021)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
Andres Poveda et al.
LANCET ONCOLOGY (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial
Carol Aghajanian et al.
GYNECOLOGIC ONCOLOGY (2021)
Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
Richard T. Penson et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials
Ilary Ruscito et al.
CANCER TREATMENT REVIEWS (2020)
Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
Michelle McMullen et al.
CANCERS (2020)
Protocol registration issues of systematic review and meta-analysis studies: a survey of global researchers
Gehad Mohamed Tawfik et al.
BMC MEDICAL RESEARCH METHODOLOGY (2020)
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial
Josep M. del Campo et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
R. L. Coleman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy
Ursula A. Matulonis et al.
CANCER (2016)
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
Jonathan A. Ledermann et al.
LANCET ONCOLOGY (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer
Shivaani Kummar et al.
CLINICAL CANCER RESEARCH (2015)
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
Amit M. Oza et al.
LANCET ONCOLOGY (2015)
Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials
Ursula A. Matulonis et al.
CANCER (2015)
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Jonathan Ledermann et al.
LANCET ONCOLOGY (2014)
Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer
Stan B. Kaye et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Practical methods for incorporating summary time-to-event data into meta-analysis
Jayne F. Tierney et al.
TRIALS (2007)